ArticleCase reports in oncology
Pathological Complete Response following Pembrolizumab Combined with Gemcitabine and Cisplatin Therapy for Initially Unresectable Intrahepatic Cholangiocarcinoma: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of biliary tract cancer; however, reports on conversion surgery following ICI-based therapy for unresectable disease are scarce. Case Presentations: An 83-year-old female was referred to a local hospital for further evaluation after abnormal liver function was detected during a routine health examination. Computed tomography (CT) revealed a 5 cm tumor in segment 4 of the liver, multiple liver metastases in both lobes, and metastasis to lymph node station 8. Biopsy of the tumor confirmed a diagnosis of intrahepatic cholangiocarcinoma, and the disease was determined to be unresectable due to distant metastases. After 10 courses of gemcitabine, cisplatin, and pembrolizumab (GCP) therapy, follow-up CT revealed marked shrinkage of the primary tumor in segment 4 of the liver, liver metastases, and lymph node station 8. Consequently, an extended left hepatectomy with partial resection of segments 6 and 8 was performed. The postoperative course was uneventful, and the patient was discharged on postoperative day 14. Histopathological examination revealed a pathological complete response (pCR). At 4 months postoperatively, the patient was alive without recurrence. Conclusion: Reports of conversion surgery following GCP therapy are scarce, and patients achieving a pCR are extremely rare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.